NUWE and BAX Related Headlines
Go Back- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
- New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
- Nuwellis (NUWE) Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
- Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
- Nuwellis (NUWE) Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
- New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
- Nuwellis Announces Board of Directors Transition
- Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
- Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
- Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
- Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
- Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
- Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
- Nuwellis, Inc. Announces Second Quarter 2023 Financial Results
- Nuwellis (NUWE) Announces CFO Transition
- Nuwellis Announces Plan for CFO Transition
- Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
- Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
- Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
- Nuwellis (NUWE) Announces Appointment of Mike McCormick to its Board of Directors
- Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis, Inc. Announces First Quarter 2023 Financial Results
NUWE and BAX Related Press Releases
Go Back- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
- New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
- Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
- New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
- Nuwellis Announces Board of Directors Transition
- Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
- Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
- Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
- Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
- Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
- Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
- Nuwellis, Inc. Announces Second Quarter 2023 Financial Results
- Nuwellis Announces Plan for CFO Transition
- Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
- Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
- Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
- Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nuwellis, Inc. Announces First Quarter 2023 Financial Results
NUWE and BAX Related SEC Filings
Go Back- Form S-1/A Nuwellis, Inc.
- Form PRE 14A Nuwellis, Inc. For: May 10
- Form 8-K Nuwellis, Inc. For: Mar 26
- Form S-1/A Nuwellis, Inc.
- Form 10-K Nuwellis, Inc. For: Dec 31
- Form 8-K Nuwellis, Inc. For: Mar 05
- Form S-1/A Nuwellis, Inc.
- Form 8-K Nuwellis, Inc. For: Feb 06
- Form S-1/A Nuwellis, Inc.
- Form S-1/A Nuwellis, Inc.
- Form S-1 Nuwellis, Inc.
- Form 8-K/A Nuwellis, Inc. For: Jan 09
- Form 8-K Nuwellis, Inc. For: Jan 08
- Form 4 Nuwellis, Inc. For: Jan 02 Filed by: McCormick Michael Kendrick
- Form 4 Nuwellis, Inc. For: Jan 02 Filed by: McDonald David
- Form 4 Nuwellis, Inc. For: Jan 02 Filed by: Feldshon Archelle Georgiou
- Form 8-K Nuwellis, Inc. For: Dec 07
- Form 10-Q Nuwellis, Inc. For: Sep 30
- Form 8-K Nuwellis, Inc. For: Nov 07
- Form 3 Nuwellis, Inc. For: Nov 01 Filed by: McDonald David
- Form 3 Nuwellis, Inc. For: Nov 01 Filed by: Feldshon Archelle Georgiou
- Form 8-K Nuwellis, Inc. For: Oct 30
- Form 8-K Nuwellis, Inc. For: Oct 12
- Form 424B4 Nuwellis, Inc.
- Form 8-K Nuwellis, Inc. For: Oct 10
- Form POS462C Nuwellis, Inc.
- Form AW Nuwellis, Inc.
- Form POS AM Nuwellis, Inc.
- Form EFFECT Nuwellis, Inc.
- Form S-1/A Nuwellis, Inc.
- Form S-1 Nuwellis, Inc.
- Form 4 Nuwellis, Inc. For: Sep 02 Filed by: Scott Robert Benjamin
- Form 3 Nuwellis, Inc. For: Sep 02 Filed by: Scott Robert Benjamin
- Form 8-K Nuwellis, Inc. For: Aug 15
- Form 10-Q Nuwellis, Inc. For: Jun 30
- Form 8-K Nuwellis, Inc. For: Aug 04
- Form 8-K Nuwellis, Inc. For: Aug 08
- Form D Nuwellis, Inc.
- Form 8-K Nuwellis, Inc. For: Jun 19
- Form 8-K Nuwellis, Inc. For: May 30
- Form 4 Nuwellis, Inc. For: Jun 01 Filed by: McCormick Michael Kendrick
- Form 3 Nuwellis, Inc. For: Jun 01 Filed by: McCormick Michael Kendrick
- Form SD Nuwellis, Inc.
- Form 4 Nuwellis, Inc. For: May 19 Filed by: Salveson Jon W
- Form 4 Nuwellis, Inc. For: May 19 Filed by: WALLER GREGORY D
- Form 4 Nuwellis, Inc. For: May 19 Filed by: WATSON WARREN S
- Form 4 Nuwellis, Inc. For: May 19 Filed by: ERB JOHN L
- Form 8-K Nuwellis, Inc. For: May 19
- Form 10-Q Nuwellis, Inc. For: Mar 31
- Form 8-K Nuwellis, Inc. For: May 09
